{"gene":"UCHL5","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2006,"finding":"UCHL5/Uch37 is responsible for the ubiquitin isopeptidase activity in the PA700 (19S) proteasome regulatory complex, specifically disassembling Lys48-linked polyubiquitin from the distal end of the chain (exo-specific activity). It is recruited to the proteasome via Adrm1 (hRpn13), which binds through proteasomal subunit S1/Rpn2. Adrm1 binds the C-terminal tail of Uch37 and relieves Uch37 autoinhibition, accelerating ubiquitin-AMC hydrolysis. Incorporation into the full 19S complex is required for efficient polyubiquitin chain processing.","method":"Biochemical fractionation, in vitro DUB activity assays (ubiquitin-AMC), mass spectrometry, Co-IP, identification of Adrm1 as hRpn13 ortholog","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal biochemical methods (activity assays, reconstitution, Co-IP, MS), replicated in a companion paper (PMID:16990800)","pmids":["16906146"],"is_preprint":false},{"year":2006,"finding":"hRpn13 (ADRM1) recruits UCH37 to 26S proteasomes via physical interaction between the KEKE-motif-containing C-terminal regions of both proteins; hRpn13 interacts with the base subunit Rpn2 via its N-terminus. Knockdown of hRpn13 causes loss of UCH37 protein levels and decreases deubiquitinating activity of 26S proteasomes, indicating hRpn13 is essential for UCH37 activity at the proteasome.","method":"Co-IP, siRNA knockdown, DUB activity assay, yeast-two-hybrid, domain mapping","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP and functional activity assay, replicated across multiple groups (PMIDs 16906146, 17139257)","pmids":["16990800"],"is_preprint":false},{"year":2006,"finding":"The C-terminal half of hRpn13 directly binds UCH37 and enhances its isopeptidase activity. Knockdown of hRpn13 in 293T cells increases cellular ubiquitin conjugates and decreases degradation of short-lived proteins. Overproduction of hRpn13 or its C-terminal half also impairs proteolysis and the latter induces cell death, acting as a dominant-negative.","method":"Affinity purification, Co-IP, siRNA knockdown, pulse-chase degradation assay, overexpression studies","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (affinity purification, Co-IP, functional assays), consistent with two other concurrent papers","pmids":["17139257"],"is_preprint":false},{"year":2008,"finding":"In addition to its proteasomal role, Uch37 is associated with the human Ino80 chromatin-remodeling complex (hINO80) in the nucleus where it is held in an inactive state. Uch37 can be activated by transient interaction of the Ino80 complex with the proteasome. Thus, Uch37 activity is modulated both positively (by proteasomal binding) and negatively (by hINO80 binding) via dynamic interactions with partner proteins.","method":"Mass spectrometry, Co-IP, in vitro DUB activity assays (ubiquitin-AMC)","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP and activity assays from a single lab, two orthogonal methods establishing dual complex membership and opposing regulation","pmids":["18922472"],"is_preprint":false},{"year":2005,"finding":"UCH37 interacts with Smad7 (and weakly with Smad2/Smad3) via a region distinct from the Smad7 PY-motif. Endogenous Smad7 and UCH37 form a stable complex. UCH37 can deubiquitinate and stabilize the type I TGF-β receptor (ALK5). Overexpression of UCH37 upregulates TGF-β-dependent transcription; RNAi-mediated knockdown reverses this effect.","method":"GST pull-down, Co-IP, overexpression, RNAi knockdown, luciferase reporter assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — GST pull-down, Co-IP, and functional reporter assay in a single lab; deubiquitination of ALK5 demonstrated but pathway details partially inferred","pmids":["16027725"],"is_preprint":false},{"year":2015,"finding":"Crystal structures of UCH37 in complex with RPN13 (DEUBAD domain) and NFRKB (INO80G DEUBAD domain) reveal that: RPN13 activates UCH37 by disrupting dimerization and stabilizing a surface competent for ubiquitin binding while modulating the active-site crossover loop; NFRKB/INO80G inhibits UCH37 by blocking the ubiquitin-binding site and disrupting the enzyme active site through molecular mimicry of ubiquitin. Both make similar contacts to the UCH37 C-terminal domain but different contacts to the catalytic UCH domain.","method":"X-ray crystallography, biochemical DUB activity assays, mutagenesis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with functional validation by biochemical assay and mutagenesis, replicated in companion paper (PMID:25702872)","pmids":["25702870"],"is_preprint":false},{"year":2015,"finding":"Crystal structures of UCH37 complexed with RPN13 and NFRKB confirm that RPN13 activates UCH37 partly by disrupting homodimerization and by stabilizing a ubiquitin-binding competent conformation; NFRKB inhibits UCH37 by blocking the ubiquitin-binding site and disrupting the active site. The UCH37 C-terminal ULD domain contacts both regulatory partners at a shared interface.","method":"X-ray crystallography, biochemical activity assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with biochemical validation, concurrent replication (PMID:25702870)","pmids":["25702872"],"is_preprint":false},{"year":2014,"finding":"Uch37 oligomerizes (autoinhibits) in solution through interactions between its C-terminal extension (Hb, Hc, KEKE motifs) that block the ubiquitin-binding site of each catalytic domain in the homodimer. Rpn13C (C-terminal domain of Rpn13) disrupts Uch37 oligomerization by sequestering Uch37 into a 1:1 complex, activating it ~12-fold by rendering the active site accessible to ubiquitin.","method":"NMR, SAXS, FRET, mutagenesis, biochemical activity assay (Ub-AMC)","journal":"Protein & cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple structural/biophysical methods (NMR, SAXS, FRET) plus activity assay and mutagenesis in a single study","pmids":["24752541"],"is_preprint":false},{"year":2013,"finding":"Crystal structures of UCH37 from Trichinella spiralis in complex with ubiquitin vinyl methyl ester (UbVME) show that the UCH37-like domain (ULD) makes direct contact with ubiquitin, stabilizing an unusual K48-E51 intramolecular salt bridge in ubiquitin that is favored only in the distal ubiquitin of a K48-linked chain, providing a structural explanation for UCH37's exo-specific deubiquitination.","method":"X-ray crystallography (UCH37-UbVME complex), mutagenesis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with mechanistic interpretation supported by mutagenesis and comparison across 39 DUB-Ub structures","pmids":["23617878"],"is_preprint":false},{"year":2011,"finding":"Crystal structure of full-length human Uch37 at 2.95 Å reveals an elongated, predominantly helical C-terminal extension with coiled-coil interactions. The catalytic domain is similar to other UCH enzymes. The structure provides the first complete view of the full-length human enzyme.","method":"X-ray crystallography","journal":"Proteins","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystal structure from single lab, limited functional validation reported in abstract","pmids":["21953935"],"is_preprint":false},{"year":2011,"finding":"Crystal structures of the UCH37 catalytic domain show the catalytic cysteine in an unproductive orientation, representing an inactive (apo) form of the enzyme. This suggests structural transitions are required for activation, and that the crossover loop plays a role in activity regulation.","method":"X-ray crystallography (two truncated catalytic domain constructs)","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystal structure from single lab; functional inference from structural observation without complementary activity assay described","pmids":["21995438"],"is_preprint":false},{"year":2009,"finding":"Crystal structure of the UCH37 catalytic domain reveals that helix-3 is collapsed (compared to UCH-L1 and UCH-L3), widening the substrate-binding P'-site and enabling UCH37 to accommodate larger adducts such as ubiquitin.","method":"X-ray crystallography, structural comparison","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystal structure from single lab, structural interpretation without functional mutagenesis validation","pmids":["19836345"],"is_preprint":false},{"year":2020,"finding":"UCH37/UCHL5 is a debranching deubiquitinase: it selectively cleaves K48-branched ubiquitin chain architectures, and this activity is markedly enhanced by proteasomal Ub receptor RPN13/ADRM1. Using reconstituted proteasome complexes, chain debranching by UCH37 promotes degradation of substrates modified with branched chains. Loss of UCH37 activity in proteome-wide pulse-chase experiments impairs global protein turnover.","method":"Synthetic and enzyme-derived ubiquitin chain substrates, intact mass spectrometry, reconstituted proteasome complexes, pulse-chase proteomics","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro reconstitution with defined substrates, MS verification, and cell-based proteomics; replicated in companion study (PMID:34761751)","pmids":["33156996"],"is_preprint":false},{"year":2021,"finding":"UCH37 debranching specificity arises from contacts with the hydrophobic patches of both distal ubiquitins emanating from a branched node. RPN13 further enhances branched-chain specificity by restricting linear Ub chains from accessing the UCH37 active site. Catalytically inactive UCH37(C88A) at the proteasome causes aberrant retention of polyubiquitinated species and the RAD23B substrate shuttle factor, suggesting defects in proteasome recycling.","method":"NMR structural analysis, biochemical assays with defined ubiquitin chain substrates, cell-based experiments with catalytically inactive mutant","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — NMR, biochemical assays with defined substrates, and cell-based functional data, single lab but multiple orthogonal methods","pmids":["34761751"],"is_preprint":false},{"year":2022,"finding":"A cryptic K48 ubiquitin chain-specific binding site exists on the opposite face of UCH37 from the canonical S1 ubiquitin-binding site. This site is required for chain debranching and proteasome-mediated degradation of proteins modified with branched chains. Targeted mutagenesis of this site impairs UCH37 debranching activity, and quantitative proteomics identifies specific substrates dependent on this site.","method":"Hydrogen-deuterium exchange mass spectrometry, chemical crosslinking, SAXS, NMR, molecular docking, mutagenesis, biochemical assays, quantitative proteomics","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple structural/biophysical methods plus mutagenesis and cell-based proteomics in a single comprehensive study","pmids":["35451368"],"is_preprint":false},{"year":2004,"finding":"In fission yeast, Uch2/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome. Disruption of the Uch2 gene is viable without obvious impairment of ubiquitin-dependent proteolysis, indicating redundancy with other DUBs.","method":"Gene disruption, DUB activity assay of proteasome fractions, genetic analysis","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical activity assay and genetic disruption in fission yeast ortholog, replicated in core concepts by mammalian studies","pmids":["15533439"],"is_preprint":false},{"year":2010,"finding":"UCH37 deletion in mice results in prenatal lethality associated with severe defects in embryonic brain development, demonstrating an essential role for Uch37 in mammalian development.","method":"Conditional knockout mouse model, histological analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean knockout with specific developmental phenotype, single study","pmids":["21048919"],"is_preprint":false},{"year":2001,"finding":"UCH37 interacts via its C-terminal extension with S14 (a PA700/19S subunit) and with UIP1 (a novel UCH37-interacting protein). UIP1 competitively blocks the UCH37–S14 interaction in vitro.","method":"Yeast two-hybrid screen, in vitro binding assay, Co-IP, domain mapping","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid confirmed by in vitro binding and Co-IP; single lab, identified before mechanistic context of hRpn13 was established","pmids":["11163772"],"is_preprint":false},{"year":2015,"finding":"UCH37 deubiquitinates Lys63-linked (but not Lys48-linked) ubiquitin chains on E2F1, without affecting E2F1 protein stability. This deubiquitination activates E2F1 transcriptional activity. UCH37 is induced by E2F1 and rises during G1/S transition, forming a positive feedback loop. UCH37 localizes to promoters of E2F1 pro-apoptotic target genes (caspase 3, caspase 7, PARP1, Apaf-1) and activates them after DNA damage.","method":"Co-IP, ubiquitination assays, catalytically dead mutant, siRNA knockdown, ChIP, luciferase reporter","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, ubiquitination assay, catalytically dead mutant, and ChIP in a single lab study","pmids":["26396186"],"is_preprint":false},{"year":2016,"finding":"hRpn13 and Uch37 are required for proper cell cycle progression; their knockdown causes stalling at G0/G1. Loss of hRpn13 correlates with a small but significant reduction in Uch37 protein levels, suggesting hRpn13 interaction stabilizes Uch37 in human cells.","method":"siRNA knockdown, FACS cell cycle analysis, protein level quantification","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean siRNA knockdown with specific cell cycle phenotype, single lab","pmids":["26907685"],"is_preprint":false},{"year":2018,"finding":"UCHL5/UCH37 interacts with and deubiquitinates Smoothened (Smo), increasing its stability and promoting its accumulation at the cell membrane. Hedgehog (Hh) signaling enhances the UCHL5–Smo interaction. RPN13, an activator of UCHL5, enhances UCHL5's effect on Smo protein levels. UCH37 regulates mammalian Hh signaling by modulating hSmo ubiquitination and stability.","method":"Co-IP, ubiquitination assay, genetic epistasis (Drosophila and mammalian), overexpression/knockdown","journal":"Journal of molecular cell biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, ubiquitination assay, and genetic evidence across two model systems, single lab","pmids":["28992318"],"is_preprint":false},{"year":2017,"finding":"Structure of hRpn13 bound to a segment of hRpn2 reveals how hRpn13 docks into the proteasome; a proline-rich C-terminal hRpn2 extension stretches across the ubiquitin-binding (Pru) domain canyon of hRpn13, blocking an RA190-binding surface. RA190 directly binds and inactivates Uch37 (in addition to hRpn13), and hRpn13-deleted cells show abrogated RA190-induced substrate accumulation at proteasomes.","method":"X-ray crystallography, biophysical binding analysis (ITC, NMR), cell-based assays, hRpn13 deletion","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — crystal structure combined with biophysical and cell-based functional validation in single comprehensive study","pmids":["28598414"],"is_preprint":false},{"year":2019,"finding":"UCH37 deletion via CRISPR/Cas9 in mammalian cells decreases levels of proteasomal Rpn13, increases ubiquitinated β-catenin, and accelerates hydrogen peroxide-stimulated β-catenin degradation. UCH37 appears to maintain Rpn13 in the proteasome and to reverse ubiquitination of specific substrates including β-catenin, inhibiting cell proliferation and motility when deleted.","method":"CRISPR/Cas9 knockout, immunoblotting, ubiquitination assay, cell proliferation and motility assays","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — CRISPR knockout with defined molecular phenotypes, single lab, limited mechanistic depth in abstract","pmids":["30726867"],"is_preprint":false},{"year":2020,"finding":"Inactive UCH37 mutant C88A causes accumulation of ubiquitinated proteins in HEK293T cells that are largely distinct from those accumulated by inactive USP14 (C114A), demonstrating non-redundant and substrate-selective roles for each proteasomal DUB. UCHL5 C88A also inhibits its own deubiquitination.","method":"Catalytically inactive mutant overexpression, ubiquitin immunoprecipitation, mass spectrometry, immunoblotting","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inactive mutant approach with MS-based substrate identification and immunoblot validation, single lab with two orthogonal methods","pmids":["31703099"],"is_preprint":false},{"year":2020,"finding":"Deletion of UCHL5 from HCT116 cells causes increased ubiquitinated protein levels in whole-cell extract and at proteasomes, showing UCHL5 activity cannot be fully compensated by other DUBs (including the two other proteasomal DUBs). Loss of full-length hRpn13 reduces UCHL5 levels, but cells expressing truncated hRpn13 (competent for UCHL5 binding but defective for proteasome interaction) maintain normal UCHL5 levels.","method":"CRISPR/Cas9 gene editing, immunoblotting, proteasome fractionation","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR gene editing with defined molecular phenotypes in two different edit conditions, single lab","pmids":["32631902"],"is_preprint":false},{"year":2021,"finding":"UCHL5 deubiquitinates NLRP3 (removing K63-linked ubiquitin chains) to promote NLRP3 inflammasome assembly and activation in HCV-infected hepatocytes. siRNA knockdown of UCHL5 or DUB inhibitors abrogated NLRP3 inflammasome assembly, reduced IL-1β maturation, and decreased HCV replication.","method":"siRNA knockdown, DUB chemical inhibitors, ubiquitination assay, NLRP3 inflammasome activation assay, IL-1β ELISA","journal":"Microbiology spectrum","confidence":"Medium","confidence_rationale":"Tier 2–3 / Weak — siRNA and chemical inhibitor evidence with functional readout; linkage specificity and direct interaction not fully established in abstract","pmids":["34431717"],"is_preprint":false},{"year":2022,"finding":"UCHL5 physically interacts with multiple domains of Axin1 protein (a scaffolder of the β-catenin destruction complex) and is required for both Axin1 stabilization and Axin1 polymerization. This deubiquitination occurs at the DIX domain of Axin1 but does not require UCH L5's catalytic activity, establishing a non-enzymatic scaffolding role for UCHL5 in Wnt signaling regulation upstream of β-catenin.","method":"Co-IP, domain mapping, functional assays (Wnt reporter), catalytically dead mutant analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, domain mapping, catalytic mutant, and functional reporter assay, single lab with multiple approaches","pmids":["35256667"],"is_preprint":false},{"year":2022,"finding":"UCH37 directly deubiquitinates and stabilizes ELK3 protein in pancreatic adenocarcinoma cells. UCH37 relies on accumulated ELK3 to drive cell growth, stem-like properties, and migration. ELK3 activates Notch1 signaling as a downstream effector.","method":"Co-IP, ubiquitination assay, overexpression/knockdown, rescue experiment with ELK3","journal":"Experimental cell research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — Co-IP and ubiquitination assay with rescue experiment, single lab, limited mechanistic depth reported in abstract","pmids":["36328194"],"is_preprint":false},{"year":2023,"finding":"ADRM1 upregulates UCH37 expression and binds UCH37 to activate its deubiquitinating activity; activated UCH37 in turn deubiquitinates and stabilizes ALK5 (TGF-β type I receptor), thereby maintaining extracellular matrix homeostasis in chondrocytes.","method":"Co-IP, ubiquitination assay, overexpression/knockout in vitro and in vivo (DMM mouse model), ADRM1 inhibitor RA190","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, ubiquitination assay, and in vivo genetic models with functional phenotype, single lab","pmids":["37406898"],"is_preprint":false},{"year":2023,"finding":"UCHL5 deubiquitinates NLRP3 to enhance its protein stability, promoting NLRP3 inflammasome activation. NLRP3 directly binds UCHL5 and maintains UCHL5 stability through reducing ubiquitin-proteasome pathway degradation in mandibular mesenchymal stem cells. UCHL5 inhibition promotes NLRP3 ubiquitination and degradation, enhancing osteoblast differentiation.","method":"Co-IP, ubiquitination analysis, UCHL5 inhibitor (b-AP15), osteoblast differentiation assay, in vivo mandibular defect model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and ubiquitination assay with in vivo validation, single lab","pmids":["36778113"],"is_preprint":false},{"year":2024,"finding":"UCHL5 modified by METTL14/YTHDF1-mediated m6A upregulation deubiquitinates NLRP3, enhancing its protein stability and promoting NLRP3 inflammasome activation in vascular smooth muscle cells, contributing to atherosclerosis progression.","method":"RIP assay, dual-luciferase reporter, Co-IP, ubiquitination analysis, siRNA knockdown, in vivo AS mouse model","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, ubiquitination assay, and in vivo model with multiple orthogonal methods, single lab","pmids":["37044315"],"is_preprint":false},{"year":2025,"finding":"USP14 and UCHL5 synergistically stabilize PKCα by removing K48-linked ubiquitination chains from PKCα, thereby facilitating nuclear translocation of NF-κB and activating pro-oncogenic genes (C-MYC, BCL-XL) in anaplastic thyroid cancer cells.","method":"Co-IP, ubiquitination assay, siRNA knockdown, nuclear fractionation, xenograft model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 / Weak — Co-IP and ubiquitination assay with nuclear fractionation, single lab, relatively recent paper","pmids":["40804247"],"is_preprint":false},{"year":2025,"finding":"Downregulation of UCHL5 by siRNA reduces autophagy in HeLa cells by partially blocking autophagosome–lysosome fusion, linking proteasomal DUB activity to autophagic flux. In C. elegans, ubh-4/UCHL5 RNAi affects autophagosome and autolysosome numbers in a tissue-dependent manner without blocking lysosomal fusion.","method":"siRNA knockdown, autophagy flux assay (autophagosome/autolysosome quantification), C. elegans RNAi","journal":"Biology open","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with specific autophagic phenotype across two model systems, single lab","pmids":["39912491"],"is_preprint":false},{"year":2024,"finding":"UCHL5 directly interacts with ZRANB1 (via Co-IP) and stabilizes ZRANB1 protein by deubiquitination, extending its half-life by over 2-fold. UCHL5 overexpression enhances ferroptosis sensitivity while UCHL5 knockout protects against ferroptosis, with UCHL5 upregulating ZRANB1 and downregulating SLC7A11/GPX4.","method":"Co-IP, ubiquitination analysis, protein half-life assay (CHX chase), CRISPR/Cas9 knockout, ferroptosis assays (BODIPY C11, GSH, Fe2+), xenograft model","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP, ubiquitination assay, and half-life assay from a single preprint-level study, single lab","pmids":["42037453"],"is_preprint":false},{"year":2025,"finding":"UCHL5 counteracts PROTAC-mediated degradation of AURKA in a manner dependent on ubiquitin ligase adaptor CRBN (but not VHL). UCHL5 acts broadly on CRBN-dependent PROTAC substrates, not specifically on AURKA, in contrast to OTUD6A which is AURKA-specific.","method":"siRNA screen (97 DUBs), orthogonal dTAG PROTACs, immunoblotting","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — siRNA-based screen with limited mechanistic follow-up reported in preprint abstract, single lab","pmids":[],"is_preprint":true},{"year":2015,"finding":"UCH37 knockdown significantly inhibits TGF-β-dependent gene reporter activity and selectively decreases levels of TGF-β target genes (p21, PAI-1) during the early phase of TGF-β receptor activation. UCH37 knockdown in Colo-357 cells impairs cell migration without affecting TGF-β-dependent proliferation or EMT.","method":"Stable/inducible knockdown cell lines, luciferase reporter, RT-PCR, cell migration assay (wound-healing/transwell)","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple orthogonal functional readouts (reporter, mRNA, migration) with stable knockdown lines, single lab","pmids":["21187158"],"is_preprint":false}],"current_model":"UCHL5/UCH37 is a UCH-family deubiquitinating enzyme that associates with two major complexes: at the 26S proteasome it is recruited via direct interaction between its C-terminal ULD domain and the DEUBAD domain of hRpn13/ADRM1 (which itself docks on Rpn2), where RPN13 relieves UCH37 autoinhibition (caused by homodimerization) to enable exo-specific and debranching deubiquitination of K48-linked polyubiquitin chains—promoting proteasomal substrate degradation; in the nucleus it associates with the hINO80 chromatin-remodeling complex via the related DEUBAD protein INO80G/NFRKB, which instead exploits molecular mimicry to lock UCH37 in an inactive conformation, with full activation requiring transient proteasome–INO80 interaction. Beyond the proteasome, UCH37 deubiquitinates additional substrates including the TGF-β type I receptor ALK5, Smoothened (Smo) in Hedgehog signaling, E2F1 (removing K63-linked chains to activate transcription), PKCα, NLRP3, ELK3, and Axin1, thereby regulating TGF-β, Hedgehog, Wnt/β-catenin, and innate immune signaling pathways; UCH37 knockout in mice causes prenatal lethality with severe brain developmental defects, underscoring its essential in vivo role."},"narrative":{"mechanistic_narrative":"UCHL5/UCH37 is a UCH-family deubiquitinating enzyme whose central function is to process Lys48-linked polyubiquitin at the 26S proteasome, where it acts exo-specifically from the distal end of the chain to support substrate degradation [PMID:16906146]. The enzyme is intrinsically autoinhibited: its C-terminal extension drives homodimerization that occludes the ubiquitin-binding site of each catalytic domain, and this oligomeric state is disrupted by the C-terminal (DEUBAD) domain of hRpn13/ADRM1, which sequesters UCH37 into an active 1:1 complex and accelerates ubiquitin hydrolysis [PMID:24752541, PMID:25702870]. hRpn13 docks UCH37 onto the proteasome by binding the base subunit Rpn2, and this interaction is required for both UCH37 activity and its protein stability in cells [PMID:16990800, PMID:17139257, PMID:32631902]. Crystallographic and biophysical work established that the UCH37 C-terminal ULD domain engages both regulatory partners at a shared interface, with hRpn13 stabilizing a ubiquitin-competent conformation while INO80G/NFRKB of the nuclear hINO80 chromatin-remodeling complex instead inhibits UCH37 by molecular mimicry of ubiquitin, locking the enzyme inactive until transient proteasome–INO80 contact relieves the block [PMID:25702870, PMID:25702872, PMID:18922472]. Beyond canonical exo-cleavage, UCH37 is a debranching deubiquitinase that selectively cleaves K48-branched chain architectures via a cryptic chain-binding site distal to the catalytic S1 site, an activity enhanced by RPN13 and required for efficient degradation of branched-chain-modified substrates and for proteasome recycling [PMID:33156996, PMID:34761751, PMID:35451368]. UCH37 activity is non-redundant with other proteasomal DUBs, acting on a substrate-selective ubiquitinome [PMID:31703099, PMID:32631902], and its loss perturbs cell-cycle progression [PMID:26907685]. Outside the proteasome, UCH37 deubiquitinates and stabilizes diverse substrates to tune signaling pathways: the TGF-β type I receptor ALK5 [PMID:16027725, PMID:37406898], Smoothened in Hedgehog signaling [PMID:28992318], and NLRP3 to promote inflammasome activation [PMID:36778113], and it removes K63-linked chains from E2F1 to activate transcription of pro-apoptotic target genes after DNA damage [PMID:26396186]. UCH37 also acts in Wnt signaling through a catalytically independent scaffolding role that stabilizes and polymerizes Axin1 [PMID:35256667]. UCH37 deletion in mice causes prenatal lethality with severe defects in embryonic brain development, establishing an essential developmental role [PMID:21048919].","teleology":[{"year":2001,"claim":"Before its proteasomal mechanism was understood, the question was which partners engage UCH37; an early screen mapped its C-terminal extension to a 19S subunit and a novel interactor, foreshadowing partner-dependent regulation.","evidence":"Yeast two-hybrid, in vitro binding and Co-IP identifying S14 and UIP1 binding the C-terminal extension","pmids":["11163772"],"confidence":"Medium","gaps":["UIP1 functional significance never integrated into later mechanistic models","predates discovery of hRpn13 as the relevant proteasomal recruiter"]},{"year":2004,"claim":"Establishing physiological relevance, the fission yeast ortholog was shown to be the major proteasome-associated DUB, but dispensable for viability, revealing functional redundancy with other DUBs.","evidence":"Gene disruption and proteasome DUB activity assays in S. pombe","pmids":["15533439"],"confidence":"Medium","gaps":["redundancy in yeast does not predict the essential mammalian role","did not identify which DUBs compensate"]},{"year":2005,"claim":"The first non-proteasomal substrate connection was made, linking UCH37 to TGF-β signaling by deubiquitinating and stabilizing the ALK5 receptor.","evidence":"GST pull-down, Co-IP, RNAi and luciferase reporter assays with Smad7 and ALK5","pmids":["16027725"],"confidence":"Medium","gaps":["chain linkage on ALK5 not defined","direct vs scaffold-mediated deubiquitination not separated"]},{"year":2006,"claim":"The core proteasomal mechanism was resolved: UCH37 provides the 19S exo-specific K48 isopeptidase activity and is recruited and de-repressed by hRpn13/ADRM1, which docks the enzyme onto Rpn2.","evidence":"Three concurrent studies using biochemical fractionation, reconstitution, Ub-AMC activity assays, Co-IP and knockdown","pmids":["16906146","16990800","17139257"],"confidence":"High","gaps":["structural basis of autoinhibition relief not yet defined","branched-chain specificity not yet appreciated"]},{"year":2008,"claim":"UCH37 regulation was shown to be bidirectional: the nuclear hINO80 complex holds it inactive, while proteasome interaction activates it, defining context-dependent control through partner complexes.","evidence":"Mass spectrometry, Co-IP and in vitro DUB activity assays defining dual complex membership","pmids":["18922472"],"confidence":"High","gaps":["physiological role of UCH37 within hINO80 chromatin remodeling not defined","in vivo trigger of proteasome–INO80 contact unknown"]},{"year":2011,"claim":"Early structural work on full-length and catalytic-domain constructs visualized the elongated C-terminal extension and an inactive active-site configuration, setting up the conformational-activation model.","evidence":"X-ray crystallography of full-length and truncated UCH37 constructs","pmids":["21953935","21995438","19836345"],"confidence":"Medium","gaps":["apo structures lacked partner or ubiquitin context","activation transitions inferred rather than captured"]},{"year":2014,"claim":"The autoinhibition mechanism was solved biophysically: the C-terminal extension mediates oligomerization that blocks the ubiquitin site, and Rpn13C disrupts this to give ~12-fold activation.","evidence":"NMR, SAXS, FRET, mutagenesis and Ub-AMC activity assays","pmids":["24752541"],"confidence":"High","gaps":["dynamics within the intact proteasome not addressed"]},{"year":2015,"claim":"Crystal structures with RPN13 and NFRKB DEUBAD domains explained opposing regulation: both bind the ULD domain but RPN13 disrupts dimerization to activate while NFRKB blocks the ubiquitin site by molecular mimicry.","evidence":"X-ray crystallography of UCH37–RPN13 and UCH37–NFRKB complexes with biochemical and mutagenesis validation","pmids":["25702870","25702872"],"confidence":"High","gaps":["does not address branched-chain selectivity","transition between inactive and active states in cells not resolved"]},{"year":2013,"claim":"A structure with ubiquitin (UbVME) explained exo-specificity: the ULD domain stabilizes a K48-E51 salt bridge unique to the distal ubiquitin of a K48 chain.","evidence":"X-ray crystallography of Trichinella UCH37–UbVME and mutagenesis","pmids":["23617878"],"confidence":"High","gaps":["ortholog structure; human-specific contacts not directly shown"]},{"year":2015,"claim":"UCH37 was shown to act in transcription by removing K63 (not K48) chains from E2F1 without affecting stability, activating E2F1 pro-apoptotic targets in a feedback loop after DNA damage.","evidence":"Co-IP, ubiquitination assays, catalytic-dead mutant, ChIP and reporter assays","pmids":["26396186"],"confidence":"Medium","gaps":["whether this occurs via hINO80 chromatin association not tested","direct vs indirect E2F1 engagement at promoters unclear"]},{"year":2016,"claim":"UCH37 and hRpn13 were linked to cell-cycle control, with knockdown causing G0/G1 stalling and hRpn13 loss reducing UCH37 levels.","evidence":"siRNA knockdown, FACS cell-cycle analysis, protein quantification","pmids":["26907685"],"confidence":"Medium","gaps":["substrates driving the arrest not identified"]},{"year":2017,"claim":"Structural work on the hRpn13–hRpn2 interface and the inhibitor RA190 clarified proteasome docking and showed RA190 directly inactivates UCH37 as well as hRpn13.","evidence":"X-ray crystallography, ITC, NMR, cell-based assays with hRpn13 deletion","pmids":["28598414"],"confidence":"High","gaps":["RA190 binding site on UCH37 itself not structurally defined"]},{"year":2020,"claim":"A redefinition of catalytic role: UCH37 is a debranching DUB that selectively cleaves K48-branched chains, an activity enhanced by RPN13 and required for degradation of branched-chain substrates.","evidence":"Defined synthetic/enzymatic chain substrates, intact MS, reconstituted proteasomes, pulse-chase proteomics","pmids":["33156996","34761751"],"confidence":"High","gaps":["fraction of cellular substrates that are branched not quantified"]},{"year":2022,"claim":"The structural basis of debranching was localized to a cryptic K48-chain binding site opposite the canonical S1 site, required for debranching and branched-substrate degradation.","evidence":"HDX-MS, crosslinking, SAXS, NMR, docking, mutagenesis and quantitative proteomics","pmids":["35451368"],"confidence":"High","gaps":["how this site is regulated within the assembled proteasome not resolved"]},{"year":2019,"claim":"Cell-based genetics confirmed UCH37 maintains proteasomal Rpn13 and acts on selective substrates such as β-catenin, linking it to Wnt-related turnover and proliferation control.","evidence":"CRISPR/Cas9 knockout, immunoblotting, ubiquitination and proliferation/motility assays","pmids":["30726867"],"confidence":"Medium","gaps":["direct vs indirect β-catenin deubiquitination not separated"]},{"year":2020,"claim":"Inactive-mutant and knockout studies established that UCH37's substrate set is non-redundant and distinct from USP14, and that hRpn13 stabilizes UCH37 specifically through binding rather than proteasome docking.","evidence":"Catalytic-dead overexpression, ubiquitin-IP MS, CRISPR editing and proteasome fractionation","pmids":["31703099","32631902"],"confidence":"Medium","gaps":["full substrate inventory not defined","rules selecting UCH37 vs USP14 substrates unknown"]},{"year":2022,"claim":"A catalysis-independent function was uncovered: UCH37 binds multiple Axin1 domains and promotes Axin1 stabilization and polymerization, acting as a scaffold in Wnt regulation upstream of β-catenin.","evidence":"Co-IP, domain mapping, catalytic-dead mutant and Wnt reporter assays","pmids":["35256667"],"confidence":"Medium","gaps":["mechanism of polymerization promotion unclear","relationship to its enzymatic β-catenin effects not reconciled"]},{"year":2018,"claim":"UCH37 was shown to regulate Hedgehog signaling by deubiquitinating and stabilizing Smoothened, an effect enhanced by RPN13.","evidence":"Co-IP, ubiquitination assays, genetic epistasis in Drosophila and mammalian cells","pmids":["28992318"],"confidence":"Medium","gaps":["chain linkage on Smo not defined","whether proteasome-associated or free UCH37 acts not resolved"]},{"year":2024,"claim":"A series of disease-context studies established UCH37 as a recurrent NLRP3 deubiquitinase that stabilizes NLRP3 and promotes inflammasome activation across hepatocytes, mesenchymal stem cells, and vascular smooth muscle.","evidence":"Co-IP, ubiquitination assays, siRNA/inhibitor, m6A regulation (RIP/luciferase) and in vivo models","pmids":["34431717","36778113","37044315"],"confidence":"Medium","gaps":["direct interaction not uniformly demonstrated","K63 vs stability mechanisms reported inconsistently across contexts"]},{"year":2025,"claim":"Additional substrate links broadened UCH37's signaling reach, stabilizing PKCα with USP14 to drive NF-κB activation, stabilizing ELK3 in pancreatic cancer, ALK5 in chondrocytes, and ZRANB1 to modulate ferroptosis, while also influencing autophagic flux.","evidence":"Co-IP, ubiquitination assays, knockdown/knockout, CHX-chase, autophagy flux and xenograft/in vivo models","pmids":["40804247","36328194","37406898","42037453","39912491"],"confidence":"Medium","gaps":["several rest on single-lab Co-IP without reciprocal validation","direct vs proteasome-indirect mechanisms not separated"]},{"year":2010,"claim":"Genetic evidence established UCH37's essentiality in mammals, with knockout causing prenatal lethality and severe brain developmental defects.","evidence":"Conditional knockout mouse model with histological analysis","pmids":["21048919"],"confidence":"Medium","gaps":["molecular pathway underlying the brain phenotype not identified","which UCH37 substrates drive lethality unknown"]},{"year":null,"claim":"How UCH37's many cytoplasmic/nuclear signaling substrates relate to its proteasome- and INO80-bound pools, and which engagements are direct catalytic versus scaffolding or proteasome-indirect, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["substrate-targeting rules for free vs complex-bound UCH37 undefined","chain linkages cleaved on many substrates not directly determined","no unifying model connecting developmental essentiality to specific substrate pathways"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,12,18,23]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,7,13]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[4,20,29,31]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[8,13,14]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[26]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,23]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,12,13]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,20,26]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[25,29,30]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[18]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[19]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[32]}],"complexes":["26S proteasome (19S/PA700 regulatory particle)","hINO80 chromatin-remodeling complex"],"partners":["ADRM1","RPN2","NFRKB","SMAD7","AXIN1","ZRANB1","NLRP3","USP14"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y5K5","full_name":"Ubiquitin carboxyl-terminal hydrolase isozyme L5","aliases":["Ubiquitin C-terminal hydrolase UCH37","Ubiquitin thioesterase L5"],"length_aa":329,"mass_kda":37.6,"function":"Protease that specifically cleaves 'Lys-48'-linked polyubiquitin chains. Deubiquitinating enzyme associated with the 19S regulatory subunit of the 26S proteasome. Putative regulatory component of the INO80 complex; however is inactive in the INO80 complex and is activated by a transient interaction of the INO80 complex with the proteasome via ADRM1","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9Y5K5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/UCHL5","classification":"Not Classified","n_dependent_lines":434,"n_total_lines":1208,"dependency_fraction":0.35927152317880795},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PSMA1","stoichiometry":10.0},{"gene":"PSMA3","stoichiometry":10.0},{"gene":"PSMA4","stoichiometry":10.0},{"gene":"PSMB2","stoichiometry":10.0},{"gene":"PSMB7","stoichiometry":10.0},{"gene":"PSMC2","stoichiometry":10.0},{"gene":"PSMC6","stoichiometry":10.0},{"gene":"PSMD1","stoichiometry":10.0},{"gene":"PSMD11","stoichiometry":10.0},{"gene":"PSMD12","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/search/UCHL5","total_profiled":1310},"omim":[{"mim_id":"610667","title":"UBIQUITIN CARBOXYL-TERMINAL HYDROLASE L5; UCHL5","url":"https://www.omim.org/entry/610667"},{"mim_id":"610650","title":"ADHESION-REGULATING MOLECULE 1; ADRM1","url":"https://www.omim.org/entry/610650"},{"mim_id":"300540","title":"HAUS AUGMIN-LIKE COMPLEX, SUBUNIT 7; HAUS7","url":"https://www.omim.org/entry/300540"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/UCHL5"},"hgnc":{"alias_symbol":["UCH37","CGI-70","INO80R"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y5K5","domains":[{"cath_id":"3.40.532.10","chopping":"14-145_161-225","consensus_level":"high","plddt":93.8761,"start":14,"end":225},{"cath_id":"1.20.58.860","chopping":"227-288","consensus_level":"high","plddt":89.7737,"start":227,"end":288}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5K5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5K5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5K5-F1-predicted_aligned_error_v6.png","plddt_mean":90.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=UCHL5","jax_strain_url":"https://www.jax.org/strain/search?query=UCHL5"},"sequence":{"accession":"Q9Y5K5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y5K5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y5K5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5K5"}},"corpus_meta":[{"pmid":"16906146","id":"PMC_16906146","title":"Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1.","date":"2006","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16906146","citation_count":293,"is_preprint":false},{"pmid":"24319254","id":"PMC_24319254","title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24319254","citation_count":274,"is_preprint":false},{"pmid":"16990800","id":"PMC_16990800","title":"A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16990800","citation_count":217,"is_preprint":false},{"pmid":"17139257","id":"PMC_17139257","title":"hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17139257","citation_count":207,"is_preprint":false},{"pmid":"16027725","id":"PMC_16027725","title":"The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16027725","citation_count":156,"is_preprint":false},{"pmid":"18922472","id":"PMC_18922472","title":"Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in the Ino80 chromatin-remodeling complex.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/18922472","citation_count":127,"is_preprint":false},{"pmid":"25702870","id":"PMC_25702870","title":"Mechanism of UCH-L5 activation and inhibition by DEUBAD domains in RPN13 and INO80G.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25702870","citation_count":106,"is_preprint":false},{"pmid":"25702872","id":"PMC_25702872","title":"Structural basis for the activation and inhibition of the UCH37 deubiquitylase.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25702872","citation_count":101,"is_preprint":false},{"pmid":"21048919","id":"PMC_21048919","title":"Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21048919","citation_count":81,"is_preprint":false},{"pmid":"28598414","id":"PMC_28598414","title":"Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28598414","citation_count":73,"is_preprint":false},{"pmid":"15533439","id":"PMC_15533439","title":"Uch2/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome in fission yeast.","date":"2004","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15533439","citation_count":73,"is_preprint":false},{"pmid":"33156996","id":"PMC_33156996","title":"Proteasome-Bound UCH37/UCHL5 Debranches Ubiquitin Chains to Promote Degradation.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33156996","citation_count":67,"is_preprint":false},{"pmid":"22615012","id":"PMC_22615012","title":"Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma.","date":"2012","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22615012","citation_count":58,"is_preprint":false},{"pmid":"25691154","id":"PMC_25691154","title":"Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.","date":"2015","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/25691154","citation_count":57,"is_preprint":false},{"pmid":"27813535","id":"PMC_27813535","title":"Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.","date":"2016","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/27813535","citation_count":53,"is_preprint":false},{"pmid":"26907685","id":"PMC_26907685","title":"The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26907685","citation_count":49,"is_preprint":false},{"pmid":"28992318","id":"PMC_28992318","title":"The deubiquitinase UCHL5/UCH37 positively regulates Hedgehog signaling by deubiquitinating Smoothened.","date":"2018","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28992318","citation_count":48,"is_preprint":false},{"pmid":"22645167","id":"PMC_22645167","title":"A common ancestry for BAP1 and Uch37 regulators.","date":"2012","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22645167","citation_count":48,"is_preprint":false},{"pmid":"32351584","id":"PMC_32351584","title":"LncRNA DRAIC inhibits proliferation and metastasis of gastric cancer cells through interfering with NFRKB deubiquitination mediated by UCHL5.","date":"2020","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32351584","citation_count":42,"is_preprint":false},{"pmid":"21995438","id":"PMC_21995438","title":"Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme.","date":"2011","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21995438","citation_count":41,"is_preprint":false},{"pmid":"21953935","id":"PMC_21953935","title":"Structural characterization of human Uch37.","date":"2011","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/21953935","citation_count":37,"is_preprint":false},{"pmid":"19836345","id":"PMC_19836345","title":"Crystal structure of the de-ubiquitinating enzyme UCH37 (human UCH-L5) catalytic domain.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19836345","citation_count":37,"is_preprint":false},{"pmid":"32596150","id":"PMC_32596150","title":"Ubiquitin C-Terminal Hydrolase L5 (UCHL5) Accelerates the Growth of Endometrial Cancer via Activating the Wnt/β-Catenin Signaling Pathway.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32596150","citation_count":36,"is_preprint":false},{"pmid":"26267804","id":"PMC_26267804","title":"Activity-Based Proteomic Profiling of Deubiquitinating Enzymes in Salmonella-Infected Macrophages Leads to Identification of Putative Function of UCH-L5 in Inflammasome Regulation.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26267804","citation_count":36,"is_preprint":false},{"pmid":"34431717","id":"PMC_34431717","title":"Deubiquitination and Activation of the NLRP3 Inflammasome by UCHL5 in HCV-Infected Cells.","date":"2021","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/34431717","citation_count":31,"is_preprint":false},{"pmid":"24752541","id":"PMC_24752541","title":"Mechanism of the Rpn13-induced activation of Uch37.","date":"2014","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/24752541","citation_count":30,"is_preprint":false},{"pmid":"26396186","id":"PMC_26396186","title":"Regulation of E2 promoter binding factor 1 (E2F1) transcriptional activity through a deubiquitinating enzyme, UCH37.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26396186","citation_count":30,"is_preprint":false},{"pmid":"21187158","id":"PMC_21187158","title":"Early phase TGFβ receptor signalling dynamics stabilised by the deubiquitinase UCH37 promotes cell migratory responses.","date":"2010","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21187158","citation_count":30,"is_preprint":false},{"pmid":"35451368","id":"PMC_35451368","title":"A cryptic K48 ubiquitin chain binding site on UCH37 is required for its role in proteasomal degradation.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35451368","citation_count":28,"is_preprint":false},{"pmid":"34761751","id":"PMC_34761751","title":"Branched ubiquitin chain binding and deubiquitination by UCH37 facilitate proteasome clearance of stress-induced inclusions.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34761751","citation_count":26,"is_preprint":false},{"pmid":"32631902","id":"PMC_32631902","title":"Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity.","date":"2020","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32631902","citation_count":25,"is_preprint":false},{"pmid":"25747657","id":"PMC_25747657","title":"Structural plasticity allows UCH37 to be primed by RPN13 or locked down by INO80G.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25747657","citation_count":25,"is_preprint":false},{"pmid":"31666925","id":"PMC_31666925","title":"The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/31666925","citation_count":25,"is_preprint":false},{"pmid":"37044315","id":"PMC_37044315","title":"METTL14/YTHDF1 axis-modified UCHL5 aggravates atherosclerosis by activating the NLRP3 inflammasome.","date":"2023","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37044315","citation_count":22,"is_preprint":false},{"pmid":"36428630","id":"PMC_36428630","title":"UCHL5 Promotes Proliferation and Migration of Bladder Cancer Cells by Activating c-Myc via AKT/mTOR Signaling.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36428630","citation_count":22,"is_preprint":false},{"pmid":"33046988","id":"PMC_33046988","title":"Deubiquitinase UCHL5 is elevated and associated with a poor clinical outcome in lung adenocarcinoma (LUAD).","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33046988","citation_count":21,"is_preprint":false},{"pmid":"36328194","id":"PMC_36328194","title":"Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD).","date":"2022","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/36328194","citation_count":20,"is_preprint":false},{"pmid":"11163772","id":"PMC_11163772","title":"Identification of two proteins, S14 and UIP1, that interact with UCH37.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11163772","citation_count":20,"is_preprint":false},{"pmid":"39702250","id":"PMC_39702250","title":"Comprehensive pan-cancer analysis indicates UCHL5 as a novel cancer biomarker and promotes cervical cancer progression through the Wnt signaling pathway.","date":"2024","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/39702250","citation_count":18,"is_preprint":false},{"pmid":"37528233","id":"PMC_37528233","title":"Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells.","date":"2023","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/37528233","citation_count":18,"is_preprint":false},{"pmid":"36090476","id":"PMC_36090476","title":"The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma.","date":"2022","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/36090476","citation_count":18,"is_preprint":false},{"pmid":"23617878","id":"PMC_23617878","title":"Stabilization of an unusual salt bridge in ubiquitin by the extra C-terminal domain of the proteasome-associated deubiquitinase UCH37 as a mechanism of its exo specificity.","date":"2013","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23617878","citation_count":18,"is_preprint":false},{"pmid":"31703099","id":"PMC_31703099","title":"Inactive USP14 and inactive UCHL5 cause accumulation of distinct ubiquitinated proteins in mammalian cells.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31703099","citation_count":17,"is_preprint":false},{"pmid":"28681694","id":"PMC_28681694","title":"UCHL5 expression associates with improved survival in lymph-node-positive rectal cancer.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28681694","citation_count":16,"is_preprint":false},{"pmid":"37934668","id":"PMC_37934668","title":"PTIR1 acts as an isoform of DDX58 and promotes tumor immune resistance through activation of UCHL5.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37934668","citation_count":15,"is_preprint":false},{"pmid":"36778113","id":"PMC_36778113","title":"NLRP3 Regulates Mandibular Healing through Interaction with UCHL5 in MSCs.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36778113","citation_count":13,"is_preprint":false},{"pmid":"35256667","id":"PMC_35256667","title":"UCHL5 controls β-catenin destruction complex function through Axin1 regulation.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35256667","citation_count":12,"is_preprint":false},{"pmid":"38773433","id":"PMC_38773433","title":"UCHL5 promotes hepatocellular carcinoma progression by promoting glycolysis through activating Wnt/β-catenin pathway.","date":"2024","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38773433","citation_count":8,"is_preprint":false},{"pmid":"30726867","id":"PMC_30726867","title":"Proteasomal deubiquitinase UCH37 inhibits degradation of β-catenin and promotes cell proliferation and motility.","date":"2019","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/30726867","citation_count":8,"is_preprint":false},{"pmid":"35971329","id":"PMC_35971329","title":"Treatment with b-AP15 to Inhibit UCHL5 and USP14 Deubiquitinating Activity and Enhance p27 and Cyclin E1 for Tumors with p53 Deficiency.","date":"2022","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/35971329","citation_count":8,"is_preprint":false},{"pmid":"36082692","id":"PMC_36082692","title":"Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia.","date":"2022","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36082692","citation_count":7,"is_preprint":false},{"pmid":"35489684","id":"PMC_35489684","title":"A ubiquitinome analysis to study the functional roles of the proteasome associated deubiquitinating enzymes USP14 and UCH37.","date":"2022","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/35489684","citation_count":7,"is_preprint":false},{"pmid":"37762005","id":"PMC_37762005","title":"The TGF-β/UCHL5/Smad2 Axis Contributes to the Pathogenesis of Placenta Accreta.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37762005","citation_count":5,"is_preprint":false},{"pmid":"37406898","id":"PMC_37406898","title":"ADRM1/RPN13 attenuates cartilage extracellular matrix degradation via enhancing UCH37-mediated ALK5 deubiquitination.","date":"2023","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37406898","citation_count":5,"is_preprint":false},{"pmid":"36648699","id":"PMC_36648699","title":"LncRNA CRNDE binds hnRNPA1 to facilitate carbon monoxide poisoning-induced delayed encephalopathy via inhibiting UCHL5-mediated SMO deubiquitination.","date":"2023","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/36648699","citation_count":5,"is_preprint":false},{"pmid":"39068672","id":"PMC_39068672","title":"Interference with ANXA8 inhibits the malignant progression of ovarian cancer by suppressing the activation of the Wnt/β-catenin signaling pathway via UCHL5.","date":"2024","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/39068672","citation_count":5,"is_preprint":false},{"pmid":"40804247","id":"PMC_40804247","title":"USP14 and UCHL5 synergistically deubiquitinate PKCα and translocate NF-κB to promote the progression of anaplastic thyroid cancer.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40804247","citation_count":4,"is_preprint":false},{"pmid":"33341501","id":"PMC_33341501","title":"Synthesis and evaluation of tiaprofenic acid-derived UCHL5 deubiquitinase inhibitors.","date":"2020","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33341501","citation_count":4,"is_preprint":false},{"pmid":"34954522","id":"PMC_34954522","title":"The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/34954522","citation_count":4,"is_preprint":false},{"pmid":"27930845","id":"PMC_27930845","title":"Isolation and Characterization of RNA Aptamers against a Proteasome-Associated Deubiquitylating Enzyme UCH37.","date":"2016","source":"Chembiochem : a European journal of chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27930845","citation_count":3,"is_preprint":false},{"pmid":"39912491","id":"PMC_39912491","title":"Impairment of proteasome-associated deubiquitinating enzyme Uchl5/UBH-4 affects autophagy.","date":"2025","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/39912491","citation_count":3,"is_preprint":false},{"pmid":"41022734","id":"PMC_41022734","title":"In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41022734","citation_count":2,"is_preprint":false},{"pmid":"19266312","id":"PMC_19266312","title":"Characterization and tissue expression of channel catfish (Ictalurus punctatus Rafinesque, 1818) ubiquitin carboxyl-terminal hydrolase L5 (UCHL5) cDNA.","date":"2009","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19266312","citation_count":2,"is_preprint":false},{"pmid":"35720124","id":"PMC_35720124","title":"Inhibiting UCH-L5: Rational Design of a Cyclic Ubiquitin-Based Peptide Inhibitor.","date":"2022","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/35720124","citation_count":2,"is_preprint":false},{"pmid":"30605979","id":"PMC_30605979","title":"[Influence of UCHL5 on proliferation and apoptosis of SW527 breast cancer cells].","date":"2018","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/30605979","citation_count":1,"is_preprint":false},{"pmid":"39604441","id":"PMC_39604441","title":"Proteasome associated function of UCH37 is evolutionarily conserved in Plasmodium parasites.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39604441","citation_count":1,"is_preprint":false},{"pmid":"41679601","id":"PMC_41679601","title":"Quinoxaline-based UCHL5 inhibitor as a next-generation proteasome-targeting anticancer agent beyond 20S inhibition.","date":"2026","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/41679601","citation_count":1,"is_preprint":false},{"pmid":"40832226","id":"PMC_40832226","title":"Site-Specific Nanobody Inhibitors of the Proteasomal Deubiquitinase UCH37.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40832226","citation_count":0,"is_preprint":false},{"pmid":"39408703","id":"PMC_39408703","title":"Targeting USP14/UCHL5: A Breakthrough Approach to Overcoming Treatment-Resistant FLT3-ITD-Positive AML.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39408703","citation_count":0,"is_preprint":false},{"pmid":"42037453","id":"PMC_42037453","title":"UCHL5 suppresses thyroid carcinoma progression via ZRANB1 stabilization and ferroptosis regulation.","date":"2026","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/42037453","citation_count":0,"is_preprint":false},{"pmid":"41113965","id":"PMC_41113965","title":"Proteasomal deubiquitinating enzyme USP14/UCHL5 inhibitor bAP15 suppresses endoplasmic reticulum stress-mediated apoptosis and tumor growth in human chondrosarcoma.","date":"2025","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/41113965","citation_count":0,"is_preprint":false},{"pmid":"36059647","id":"PMC_36059647","title":"Corrigendum: Ubiquitin C-Terminal hydrolase L5 (UCHL5) accelerates the growth of endometrial cancer via activating the Wnt/β-catenin signaling pathway.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36059647","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.13.670075","title":"USP15: the fourth Proteasome-associated DUB","date":"2025-08-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.13.670075","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.23.650020","title":"Efficiency and localisation of AURKA degradation by PROTACs is modulated by deubiquitinases UCHL5 and target-selective OTUD6A","date":"2025-04-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.23.650020","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":39137,"output_tokens":9008,"usd":0.126266,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18874,"output_tokens":6275,"usd":0.125622,"stage2_stop_reason":"end_turn"},"total_usd":0.251888,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"UCHL5/Uch37 is responsible for the ubiquitin isopeptidase activity in the PA700 (19S) proteasome regulatory complex, specifically disassembling Lys48-linked polyubiquitin from the distal end of the chain (exo-specific activity). It is recruited to the proteasome via Adrm1 (hRpn13), which binds through proteasomal subunit S1/Rpn2. Adrm1 binds the C-terminal tail of Uch37 and relieves Uch37 autoinhibition, accelerating ubiquitin-AMC hydrolysis. Incorporation into the full 19S complex is required for efficient polyubiquitin chain processing.\",\n      \"method\": \"Biochemical fractionation, in vitro DUB activity assays (ubiquitin-AMC), mass spectrometry, Co-IP, identification of Adrm1 as hRpn13 ortholog\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal biochemical methods (activity assays, reconstitution, Co-IP, MS), replicated in a companion paper (PMID:16990800)\",\n      \"pmids\": [\"16906146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"hRpn13 (ADRM1) recruits UCH37 to 26S proteasomes via physical interaction between the KEKE-motif-containing C-terminal regions of both proteins; hRpn13 interacts with the base subunit Rpn2 via its N-terminus. Knockdown of hRpn13 causes loss of UCH37 protein levels and decreases deubiquitinating activity of 26S proteasomes, indicating hRpn13 is essential for UCH37 activity at the proteasome.\",\n      \"method\": \"Co-IP, siRNA knockdown, DUB activity assay, yeast-two-hybrid, domain mapping\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP and functional activity assay, replicated across multiple groups (PMIDs 16906146, 17139257)\",\n      \"pmids\": [\"16990800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The C-terminal half of hRpn13 directly binds UCH37 and enhances its isopeptidase activity. Knockdown of hRpn13 in 293T cells increases cellular ubiquitin conjugates and decreases degradation of short-lived proteins. Overproduction of hRpn13 or its C-terminal half also impairs proteolysis and the latter induces cell death, acting as a dominant-negative.\",\n      \"method\": \"Affinity purification, Co-IP, siRNA knockdown, pulse-chase degradation assay, overexpression studies\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (affinity purification, Co-IP, functional assays), consistent with two other concurrent papers\",\n      \"pmids\": [\"17139257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In addition to its proteasomal role, Uch37 is associated with the human Ino80 chromatin-remodeling complex (hINO80) in the nucleus where it is held in an inactive state. Uch37 can be activated by transient interaction of the Ino80 complex with the proteasome. Thus, Uch37 activity is modulated both positively (by proteasomal binding) and negatively (by hINO80 binding) via dynamic interactions with partner proteins.\",\n      \"method\": \"Mass spectrometry, Co-IP, in vitro DUB activity assays (ubiquitin-AMC)\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and activity assays from a single lab, two orthogonal methods establishing dual complex membership and opposing regulation\",\n      \"pmids\": [\"18922472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"UCH37 interacts with Smad7 (and weakly with Smad2/Smad3) via a region distinct from the Smad7 PY-motif. Endogenous Smad7 and UCH37 form a stable complex. UCH37 can deubiquitinate and stabilize the type I TGF-β receptor (ALK5). Overexpression of UCH37 upregulates TGF-β-dependent transcription; RNAi-mediated knockdown reverses this effect.\",\n      \"method\": \"GST pull-down, Co-IP, overexpression, RNAi knockdown, luciferase reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — GST pull-down, Co-IP, and functional reporter assay in a single lab; deubiquitination of ALK5 demonstrated but pathway details partially inferred\",\n      \"pmids\": [\"16027725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structures of UCH37 in complex with RPN13 (DEUBAD domain) and NFRKB (INO80G DEUBAD domain) reveal that: RPN13 activates UCH37 by disrupting dimerization and stabilizing a surface competent for ubiquitin binding while modulating the active-site crossover loop; NFRKB/INO80G inhibits UCH37 by blocking the ubiquitin-binding site and disrupting the enzyme active site through molecular mimicry of ubiquitin. Both make similar contacts to the UCH37 C-terminal domain but different contacts to the catalytic UCH domain.\",\n      \"method\": \"X-ray crystallography, biochemical DUB activity assays, mutagenesis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with functional validation by biochemical assay and mutagenesis, replicated in companion paper (PMID:25702872)\",\n      \"pmids\": [\"25702870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structures of UCH37 complexed with RPN13 and NFRKB confirm that RPN13 activates UCH37 partly by disrupting homodimerization and by stabilizing a ubiquitin-binding competent conformation; NFRKB inhibits UCH37 by blocking the ubiquitin-binding site and disrupting the active site. The UCH37 C-terminal ULD domain contacts both regulatory partners at a shared interface.\",\n      \"method\": \"X-ray crystallography, biochemical activity assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with biochemical validation, concurrent replication (PMID:25702870)\",\n      \"pmids\": [\"25702872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Uch37 oligomerizes (autoinhibits) in solution through interactions between its C-terminal extension (Hb, Hc, KEKE motifs) that block the ubiquitin-binding site of each catalytic domain in the homodimer. Rpn13C (C-terminal domain of Rpn13) disrupts Uch37 oligomerization by sequestering Uch37 into a 1:1 complex, activating it ~12-fold by rendering the active site accessible to ubiquitin.\",\n      \"method\": \"NMR, SAXS, FRET, mutagenesis, biochemical activity assay (Ub-AMC)\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple structural/biophysical methods (NMR, SAXS, FRET) plus activity assay and mutagenesis in a single study\",\n      \"pmids\": [\"24752541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structures of UCH37 from Trichinella spiralis in complex with ubiquitin vinyl methyl ester (UbVME) show that the UCH37-like domain (ULD) makes direct contact with ubiquitin, stabilizing an unusual K48-E51 intramolecular salt bridge in ubiquitin that is favored only in the distal ubiquitin of a K48-linked chain, providing a structural explanation for UCH37's exo-specific deubiquitination.\",\n      \"method\": \"X-ray crystallography (UCH37-UbVME complex), mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with mechanistic interpretation supported by mutagenesis and comparison across 39 DUB-Ub structures\",\n      \"pmids\": [\"23617878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of full-length human Uch37 at 2.95 Å reveals an elongated, predominantly helical C-terminal extension with coiled-coil interactions. The catalytic domain is similar to other UCH enzymes. The structure provides the first complete view of the full-length human enzyme.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Proteins\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystal structure from single lab, limited functional validation reported in abstract\",\n      \"pmids\": [\"21953935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structures of the UCH37 catalytic domain show the catalytic cysteine in an unproductive orientation, representing an inactive (apo) form of the enzyme. This suggests structural transitions are required for activation, and that the crossover loop plays a role in activity regulation.\",\n      \"method\": \"X-ray crystallography (two truncated catalytic domain constructs)\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystal structure from single lab; functional inference from structural observation without complementary activity assay described\",\n      \"pmids\": [\"21995438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Crystal structure of the UCH37 catalytic domain reveals that helix-3 is collapsed (compared to UCH-L1 and UCH-L3), widening the substrate-binding P'-site and enabling UCH37 to accommodate larger adducts such as ubiquitin.\",\n      \"method\": \"X-ray crystallography, structural comparison\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystal structure from single lab, structural interpretation without functional mutagenesis validation\",\n      \"pmids\": [\"19836345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UCH37/UCHL5 is a debranching deubiquitinase: it selectively cleaves K48-branched ubiquitin chain architectures, and this activity is markedly enhanced by proteasomal Ub receptor RPN13/ADRM1. Using reconstituted proteasome complexes, chain debranching by UCH37 promotes degradation of substrates modified with branched chains. Loss of UCH37 activity in proteome-wide pulse-chase experiments impairs global protein turnover.\",\n      \"method\": \"Synthetic and enzyme-derived ubiquitin chain substrates, intact mass spectrometry, reconstituted proteasome complexes, pulse-chase proteomics\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro reconstitution with defined substrates, MS verification, and cell-based proteomics; replicated in companion study (PMID:34761751)\",\n      \"pmids\": [\"33156996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UCH37 debranching specificity arises from contacts with the hydrophobic patches of both distal ubiquitins emanating from a branched node. RPN13 further enhances branched-chain specificity by restricting linear Ub chains from accessing the UCH37 active site. Catalytically inactive UCH37(C88A) at the proteasome causes aberrant retention of polyubiquitinated species and the RAD23B substrate shuttle factor, suggesting defects in proteasome recycling.\",\n      \"method\": \"NMR structural analysis, biochemical assays with defined ubiquitin chain substrates, cell-based experiments with catalytically inactive mutant\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — NMR, biochemical assays with defined substrates, and cell-based functional data, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"34761751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A cryptic K48 ubiquitin chain-specific binding site exists on the opposite face of UCH37 from the canonical S1 ubiquitin-binding site. This site is required for chain debranching and proteasome-mediated degradation of proteins modified with branched chains. Targeted mutagenesis of this site impairs UCH37 debranching activity, and quantitative proteomics identifies specific substrates dependent on this site.\",\n      \"method\": \"Hydrogen-deuterium exchange mass spectrometry, chemical crosslinking, SAXS, NMR, molecular docking, mutagenesis, biochemical assays, quantitative proteomics\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple structural/biophysical methods plus mutagenesis and cell-based proteomics in a single comprehensive study\",\n      \"pmids\": [\"35451368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In fission yeast, Uch2/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome. Disruption of the Uch2 gene is viable without obvious impairment of ubiquitin-dependent proteolysis, indicating redundancy with other DUBs.\",\n      \"method\": \"Gene disruption, DUB activity assay of proteasome fractions, genetic analysis\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical activity assay and genetic disruption in fission yeast ortholog, replicated in core concepts by mammalian studies\",\n      \"pmids\": [\"15533439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"UCH37 deletion in mice results in prenatal lethality associated with severe defects in embryonic brain development, demonstrating an essential role for Uch37 in mammalian development.\",\n      \"method\": \"Conditional knockout mouse model, histological analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean knockout with specific developmental phenotype, single study\",\n      \"pmids\": [\"21048919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"UCH37 interacts via its C-terminal extension with S14 (a PA700/19S subunit) and with UIP1 (a novel UCH37-interacting protein). UIP1 competitively blocks the UCH37–S14 interaction in vitro.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro binding assay, Co-IP, domain mapping\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid confirmed by in vitro binding and Co-IP; single lab, identified before mechanistic context of hRpn13 was established\",\n      \"pmids\": [\"11163772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"UCH37 deubiquitinates Lys63-linked (but not Lys48-linked) ubiquitin chains on E2F1, without affecting E2F1 protein stability. This deubiquitination activates E2F1 transcriptional activity. UCH37 is induced by E2F1 and rises during G1/S transition, forming a positive feedback loop. UCH37 localizes to promoters of E2F1 pro-apoptotic target genes (caspase 3, caspase 7, PARP1, Apaf-1) and activates them after DNA damage.\",\n      \"method\": \"Co-IP, ubiquitination assays, catalytically dead mutant, siRNA knockdown, ChIP, luciferase reporter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, ubiquitination assay, catalytically dead mutant, and ChIP in a single lab study\",\n      \"pmids\": [\"26396186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"hRpn13 and Uch37 are required for proper cell cycle progression; their knockdown causes stalling at G0/G1. Loss of hRpn13 correlates with a small but significant reduction in Uch37 protein levels, suggesting hRpn13 interaction stabilizes Uch37 in human cells.\",\n      \"method\": \"siRNA knockdown, FACS cell cycle analysis, protein level quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean siRNA knockdown with specific cell cycle phenotype, single lab\",\n      \"pmids\": [\"26907685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"UCHL5/UCH37 interacts with and deubiquitinates Smoothened (Smo), increasing its stability and promoting its accumulation at the cell membrane. Hedgehog (Hh) signaling enhances the UCHL5–Smo interaction. RPN13, an activator of UCHL5, enhances UCHL5's effect on Smo protein levels. UCH37 regulates mammalian Hh signaling by modulating hSmo ubiquitination and stability.\",\n      \"method\": \"Co-IP, ubiquitination assay, genetic epistasis (Drosophila and mammalian), overexpression/knockdown\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, ubiquitination assay, and genetic evidence across two model systems, single lab\",\n      \"pmids\": [\"28992318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Structure of hRpn13 bound to a segment of hRpn2 reveals how hRpn13 docks into the proteasome; a proline-rich C-terminal hRpn2 extension stretches across the ubiquitin-binding (Pru) domain canyon of hRpn13, blocking an RA190-binding surface. RA190 directly binds and inactivates Uch37 (in addition to hRpn13), and hRpn13-deleted cells show abrogated RA190-induced substrate accumulation at proteasomes.\",\n      \"method\": \"X-ray crystallography, biophysical binding analysis (ITC, NMR), cell-based assays, hRpn13 deletion\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — crystal structure combined with biophysical and cell-based functional validation in single comprehensive study\",\n      \"pmids\": [\"28598414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"UCH37 deletion via CRISPR/Cas9 in mammalian cells decreases levels of proteasomal Rpn13, increases ubiquitinated β-catenin, and accelerates hydrogen peroxide-stimulated β-catenin degradation. UCH37 appears to maintain Rpn13 in the proteasome and to reverse ubiquitination of specific substrates including β-catenin, inhibiting cell proliferation and motility when deleted.\",\n      \"method\": \"CRISPR/Cas9 knockout, immunoblotting, ubiquitination assay, cell proliferation and motility assays\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — CRISPR knockout with defined molecular phenotypes, single lab, limited mechanistic depth in abstract\",\n      \"pmids\": [\"30726867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Inactive UCH37 mutant C88A causes accumulation of ubiquitinated proteins in HEK293T cells that are largely distinct from those accumulated by inactive USP14 (C114A), demonstrating non-redundant and substrate-selective roles for each proteasomal DUB. UCHL5 C88A also inhibits its own deubiquitination.\",\n      \"method\": \"Catalytically inactive mutant overexpression, ubiquitin immunoprecipitation, mass spectrometry, immunoblotting\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inactive mutant approach with MS-based substrate identification and immunoblot validation, single lab with two orthogonal methods\",\n      \"pmids\": [\"31703099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Deletion of UCHL5 from HCT116 cells causes increased ubiquitinated protein levels in whole-cell extract and at proteasomes, showing UCHL5 activity cannot be fully compensated by other DUBs (including the two other proteasomal DUBs). Loss of full-length hRpn13 reduces UCHL5 levels, but cells expressing truncated hRpn13 (competent for UCHL5 binding but defective for proteasome interaction) maintain normal UCHL5 levels.\",\n      \"method\": \"CRISPR/Cas9 gene editing, immunoblotting, proteasome fractionation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR gene editing with defined molecular phenotypes in two different edit conditions, single lab\",\n      \"pmids\": [\"32631902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UCHL5 deubiquitinates NLRP3 (removing K63-linked ubiquitin chains) to promote NLRP3 inflammasome assembly and activation in HCV-infected hepatocytes. siRNA knockdown of UCHL5 or DUB inhibitors abrogated NLRP3 inflammasome assembly, reduced IL-1β maturation, and decreased HCV replication.\",\n      \"method\": \"siRNA knockdown, DUB chemical inhibitors, ubiquitination assay, NLRP3 inflammasome activation assay, IL-1β ELISA\",\n      \"journal\": \"Microbiology spectrum\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Weak — siRNA and chemical inhibitor evidence with functional readout; linkage specificity and direct interaction not fully established in abstract\",\n      \"pmids\": [\"34431717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"UCHL5 physically interacts with multiple domains of Axin1 protein (a scaffolder of the β-catenin destruction complex) and is required for both Axin1 stabilization and Axin1 polymerization. This deubiquitination occurs at the DIX domain of Axin1 but does not require UCH L5's catalytic activity, establishing a non-enzymatic scaffolding role for UCHL5 in Wnt signaling regulation upstream of β-catenin.\",\n      \"method\": \"Co-IP, domain mapping, functional assays (Wnt reporter), catalytically dead mutant analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, domain mapping, catalytic mutant, and functional reporter assay, single lab with multiple approaches\",\n      \"pmids\": [\"35256667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"UCH37 directly deubiquitinates and stabilizes ELK3 protein in pancreatic adenocarcinoma cells. UCH37 relies on accumulated ELK3 to drive cell growth, stem-like properties, and migration. ELK3 activates Notch1 signaling as a downstream effector.\",\n      \"method\": \"Co-IP, ubiquitination assay, overexpression/knockdown, rescue experiment with ELK3\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — Co-IP and ubiquitination assay with rescue experiment, single lab, limited mechanistic depth reported in abstract\",\n      \"pmids\": [\"36328194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADRM1 upregulates UCH37 expression and binds UCH37 to activate its deubiquitinating activity; activated UCH37 in turn deubiquitinates and stabilizes ALK5 (TGF-β type I receptor), thereby maintaining extracellular matrix homeostasis in chondrocytes.\",\n      \"method\": \"Co-IP, ubiquitination assay, overexpression/knockout in vitro and in vivo (DMM mouse model), ADRM1 inhibitor RA190\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, ubiquitination assay, and in vivo genetic models with functional phenotype, single lab\",\n      \"pmids\": [\"37406898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"UCHL5 deubiquitinates NLRP3 to enhance its protein stability, promoting NLRP3 inflammasome activation. NLRP3 directly binds UCHL5 and maintains UCHL5 stability through reducing ubiquitin-proteasome pathway degradation in mandibular mesenchymal stem cells. UCHL5 inhibition promotes NLRP3 ubiquitination and degradation, enhancing osteoblast differentiation.\",\n      \"method\": \"Co-IP, ubiquitination analysis, UCHL5 inhibitor (b-AP15), osteoblast differentiation assay, in vivo mandibular defect model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and ubiquitination assay with in vivo validation, single lab\",\n      \"pmids\": [\"36778113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"UCHL5 modified by METTL14/YTHDF1-mediated m6A upregulation deubiquitinates NLRP3, enhancing its protein stability and promoting NLRP3 inflammasome activation in vascular smooth muscle cells, contributing to atherosclerosis progression.\",\n      \"method\": \"RIP assay, dual-luciferase reporter, Co-IP, ubiquitination analysis, siRNA knockdown, in vivo AS mouse model\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, ubiquitination assay, and in vivo model with multiple orthogonal methods, single lab\",\n      \"pmids\": [\"37044315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"USP14 and UCHL5 synergistically stabilize PKCα by removing K48-linked ubiquitination chains from PKCα, thereby facilitating nuclear translocation of NF-κB and activating pro-oncogenic genes (C-MYC, BCL-XL) in anaplastic thyroid cancer cells.\",\n      \"method\": \"Co-IP, ubiquitination assay, siRNA knockdown, nuclear fractionation, xenograft model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Weak — Co-IP and ubiquitination assay with nuclear fractionation, single lab, relatively recent paper\",\n      \"pmids\": [\"40804247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Downregulation of UCHL5 by siRNA reduces autophagy in HeLa cells by partially blocking autophagosome–lysosome fusion, linking proteasomal DUB activity to autophagic flux. In C. elegans, ubh-4/UCHL5 RNAi affects autophagosome and autolysosome numbers in a tissue-dependent manner without blocking lysosomal fusion.\",\n      \"method\": \"siRNA knockdown, autophagy flux assay (autophagosome/autolysosome quantification), C. elegans RNAi\",\n      \"journal\": \"Biology open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with specific autophagic phenotype across two model systems, single lab\",\n      \"pmids\": [\"39912491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"UCHL5 directly interacts with ZRANB1 (via Co-IP) and stabilizes ZRANB1 protein by deubiquitination, extending its half-life by over 2-fold. UCHL5 overexpression enhances ferroptosis sensitivity while UCHL5 knockout protects against ferroptosis, with UCHL5 upregulating ZRANB1 and downregulating SLC7A11/GPX4.\",\n      \"method\": \"Co-IP, ubiquitination analysis, protein half-life assay (CHX chase), CRISPR/Cas9 knockout, ferroptosis assays (BODIPY C11, GSH, Fe2+), xenograft model\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP, ubiquitination assay, and half-life assay from a single preprint-level study, single lab\",\n      \"pmids\": [\"42037453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UCHL5 counteracts PROTAC-mediated degradation of AURKA in a manner dependent on ubiquitin ligase adaptor CRBN (but not VHL). UCHL5 acts broadly on CRBN-dependent PROTAC substrates, not specifically on AURKA, in contrast to OTUD6A which is AURKA-specific.\",\n      \"method\": \"siRNA screen (97 DUBs), orthogonal dTAG PROTACs, immunoblotting\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — siRNA-based screen with limited mechanistic follow-up reported in preprint abstract, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"UCH37 knockdown significantly inhibits TGF-β-dependent gene reporter activity and selectively decreases levels of TGF-β target genes (p21, PAI-1) during the early phase of TGF-β receptor activation. UCH37 knockdown in Colo-357 cells impairs cell migration without affecting TGF-β-dependent proliferation or EMT.\",\n      \"method\": \"Stable/inducible knockdown cell lines, luciferase reporter, RT-PCR, cell migration assay (wound-healing/transwell)\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple orthogonal functional readouts (reporter, mRNA, migration) with stable knockdown lines, single lab\",\n      \"pmids\": [\"21187158\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"UCHL5/UCH37 is a UCH-family deubiquitinating enzyme that associates with two major complexes: at the 26S proteasome it is recruited via direct interaction between its C-terminal ULD domain and the DEUBAD domain of hRpn13/ADRM1 (which itself docks on Rpn2), where RPN13 relieves UCH37 autoinhibition (caused by homodimerization) to enable exo-specific and debranching deubiquitination of K48-linked polyubiquitin chains—promoting proteasomal substrate degradation; in the nucleus it associates with the hINO80 chromatin-remodeling complex via the related DEUBAD protein INO80G/NFRKB, which instead exploits molecular mimicry to lock UCH37 in an inactive conformation, with full activation requiring transient proteasome–INO80 interaction. Beyond the proteasome, UCH37 deubiquitinates additional substrates including the TGF-β type I receptor ALK5, Smoothened (Smo) in Hedgehog signaling, E2F1 (removing K63-linked chains to activate transcription), PKCα, NLRP3, ELK3, and Axin1, thereby regulating TGF-β, Hedgehog, Wnt/β-catenin, and innate immune signaling pathways; UCH37 knockout in mice causes prenatal lethality with severe brain developmental defects, underscoring its essential in vivo role.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"UCHL5/UCH37 is a UCH-family deubiquitinating enzyme whose central function is to process Lys48-linked polyubiquitin at the 26S proteasome, where it acts exo-specifically from the distal end of the chain to support substrate degradation [#0]. The enzyme is intrinsically autoinhibited: its C-terminal extension drives homodimerization that occludes the ubiquitin-binding site of each catalytic domain, and this oligomeric state is disrupted by the C-terminal (DEUBAD) domain of hRpn13/ADRM1, which sequesters UCH37 into an active 1:1 complex and accelerates ubiquitin hydrolysis [#7, #5]. hRpn13 docks UCH37 onto the proteasome by binding the base subunit Rpn2, and this interaction is required for both UCH37 activity and its protein stability in cells [#1, #2, #24]. Crystallographic and biophysical work established that the UCH37 C-terminal ULD domain engages both regulatory partners at a shared interface, with hRpn13 stabilizing a ubiquitin-competent conformation while INO80G/NFRKB of the nuclear hINO80 chromatin-remodeling complex instead inhibits UCH37 by molecular mimicry of ubiquitin, locking the enzyme inactive until transient proteasome–INO80 contact relieves the block [#5, #6, #3]. Beyond canonical exo-cleavage, UCH37 is a debranching deubiquitinase that selectively cleaves K48-branched chain architectures via a cryptic chain-binding site distal to the catalytic S1 site, an activity enhanced by RPN13 and required for efficient degradation of branched-chain-modified substrates and for proteasome recycling [#12, #13, #14]. UCH37 activity is non-redundant with other proteasomal DUBs, acting on a substrate-selective ubiquitinome [#23, #24], and its loss perturbs cell-cycle progression [#19]. Outside the proteasome, UCH37 deubiquitinates and stabilizes diverse substrates to tune signaling pathways: the TGF-\\u03b2 type I receptor ALK5 [#4, #28], Smoothened in Hedgehog signaling [#20], and NLRP3 to promote inflammasome activation [#29], and it removes K63-linked chains from E2F1 to activate transcription of pro-apoptotic target genes after DNA damage [#18]. UCH37 also acts in Wnt signaling through a catalytically independent scaffolding role that stabilizes and polymerizes Axin1 [#26]. UCH37 deletion in mice causes prenatal lethality with severe defects in embryonic brain development, establishing an essential developmental role [#16].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Before its proteasomal mechanism was understood, the question was which partners engage UCH37; an early screen mapped its C-terminal extension to a 19S subunit and a novel interactor, foreshadowing partner-dependent regulation.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro binding and Co-IP identifying S14 and UIP1 binding the C-terminal extension\",\n      \"pmids\": [\"11163772\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"UIP1 functional significance never integrated into later mechanistic models\", \"predates discovery of hRpn13 as the relevant proteasomal recruiter\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing physiological relevance, the fission yeast ortholog was shown to be the major proteasome-associated DUB, but dispensable for viability, revealing functional redundancy with other DUBs.\",\n      \"evidence\": \"Gene disruption and proteasome DUB activity assays in S. pombe\",\n      \"pmids\": [\"15533439\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"redundancy in yeast does not predict the essential mammalian role\", \"did not identify which DUBs compensate\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The first non-proteasomal substrate connection was made, linking UCH37 to TGF-\\u03b2 signaling by deubiquitinating and stabilizing the ALK5 receptor.\",\n      \"evidence\": \"GST pull-down, Co-IP, RNAi and luciferase reporter assays with Smad7 and ALK5\",\n      \"pmids\": [\"16027725\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"chain linkage on ALK5 not defined\", \"direct vs scaffold-mediated deubiquitination not separated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The core proteasomal mechanism was resolved: UCH37 provides the 19S exo-specific K48 isopeptidase activity and is recruited and de-repressed by hRpn13/ADRM1, which docks the enzyme onto Rpn2.\",\n      \"evidence\": \"Three concurrent studies using biochemical fractionation, reconstitution, Ub-AMC activity assays, Co-IP and knockdown\",\n      \"pmids\": [\"16906146\", \"16990800\", \"17139257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structural basis of autoinhibition relief not yet defined\", \"branched-chain specificity not yet appreciated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"UCH37 regulation was shown to be bidirectional: the nuclear hINO80 complex holds it inactive, while proteasome interaction activates it, defining context-dependent control through partner complexes.\",\n      \"evidence\": \"Mass spectrometry, Co-IP and in vitro DUB activity assays defining dual complex membership\",\n      \"pmids\": [\"18922472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"physiological role of UCH37 within hINO80 chromatin remodeling not defined\", \"in vivo trigger of proteasome\\u2013INO80 contact unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Early structural work on full-length and catalytic-domain constructs visualized the elongated C-terminal extension and an inactive active-site configuration, setting up the conformational-activation model.\",\n      \"evidence\": \"X-ray crystallography of full-length and truncated UCH37 constructs\",\n      \"pmids\": [\"21953935\", \"21995438\", \"19836345\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"apo structures lacked partner or ubiquitin context\", \"activation transitions inferred rather than captured\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The autoinhibition mechanism was solved biophysically: the C-terminal extension mediates oligomerization that blocks the ubiquitin site, and Rpn13C disrupts this to give ~12-fold activation.\",\n      \"evidence\": \"NMR, SAXS, FRET, mutagenesis and Ub-AMC activity assays\",\n      \"pmids\": [\"24752541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"dynamics within the intact proteasome not addressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Crystal structures with RPN13 and NFRKB DEUBAD domains explained opposing regulation: both bind the ULD domain but RPN13 disrupts dimerization to activate while NFRKB blocks the ubiquitin site by molecular mimicry.\",\n      \"evidence\": \"X-ray crystallography of UCH37\\u2013RPN13 and UCH37\\u2013NFRKB complexes with biochemical and mutagenesis validation\",\n      \"pmids\": [\"25702870\", \"25702872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"does not address branched-chain selectivity\", \"transition between inactive and active states in cells not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A structure with ubiquitin (UbVME) explained exo-specificity: the ULD domain stabilizes a K48-E51 salt bridge unique to the distal ubiquitin of a K48 chain.\",\n      \"evidence\": \"X-ray crystallography of Trichinella UCH37\\u2013UbVME and mutagenesis\",\n      \"pmids\": [\"23617878\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ortholog structure; human-specific contacts not directly shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"UCH37 was shown to act in transcription by removing K63 (not K48) chains from E2F1 without affecting stability, activating E2F1 pro-apoptotic targets in a feedback loop after DNA damage.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, catalytic-dead mutant, ChIP and reporter assays\",\n      \"pmids\": [\"26396186\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"whether this occurs via hINO80 chromatin association not tested\", \"direct vs indirect E2F1 engagement at promoters unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"UCH37 and hRpn13 were linked to cell-cycle control, with knockdown causing G0/G1 stalling and hRpn13 loss reducing UCH37 levels.\",\n      \"evidence\": \"siRNA knockdown, FACS cell-cycle analysis, protein quantification\",\n      \"pmids\": [\"26907685\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"substrates driving the arrest not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Structural work on the hRpn13\\u2013hRpn2 interface and the inhibitor RA190 clarified proteasome docking and showed RA190 directly inactivates UCH37 as well as hRpn13.\",\n      \"evidence\": \"X-ray crystallography, ITC, NMR, cell-based assays with hRpn13 deletion\",\n      \"pmids\": [\"28598414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RA190 binding site on UCH37 itself not structurally defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A redefinition of catalytic role: UCH37 is a debranching DUB that selectively cleaves K48-branched chains, an activity enhanced by RPN13 and required for degradation of branched-chain substrates.\",\n      \"evidence\": \"Defined synthetic/enzymatic chain substrates, intact MS, reconstituted proteasomes, pulse-chase proteomics\",\n      \"pmids\": [\"33156996\", \"34761751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"fraction of cellular substrates that are branched not quantified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The structural basis of debranching was localized to a cryptic K48-chain binding site opposite the canonical S1 site, required for debranching and branched-substrate degradation.\",\n      \"evidence\": \"HDX-MS, crosslinking, SAXS, NMR, docking, mutagenesis and quantitative proteomics\",\n      \"pmids\": [\"35451368\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"how this site is regulated within the assembled proteasome not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Cell-based genetics confirmed UCH37 maintains proteasomal Rpn13 and acts on selective substrates such as \\u03b2-catenin, linking it to Wnt-related turnover and proliferation control.\",\n      \"evidence\": \"CRISPR/Cas9 knockout, immunoblotting, ubiquitination and proliferation/motility assays\",\n      \"pmids\": [\"30726867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"direct vs indirect \\u03b2-catenin deubiquitination not separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Inactive-mutant and knockout studies established that UCH37's substrate set is non-redundant and distinct from USP14, and that hRpn13 stabilizes UCH37 specifically through binding rather than proteasome docking.\",\n      \"evidence\": \"Catalytic-dead overexpression, ubiquitin-IP MS, CRISPR editing and proteasome fractionation\",\n      \"pmids\": [\"31703099\", \"32631902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"full substrate inventory not defined\", \"rules selecting UCH37 vs USP14 substrates unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A catalysis-independent function was uncovered: UCH37 binds multiple Axin1 domains and promotes Axin1 stabilization and polymerization, acting as a scaffold in Wnt regulation upstream of \\u03b2-catenin.\",\n      \"evidence\": \"Co-IP, domain mapping, catalytic-dead mutant and Wnt reporter assays\",\n      \"pmids\": [\"35256667\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mechanism of polymerization promotion unclear\", \"relationship to its enzymatic \\u03b2-catenin effects not reconciled\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"UCH37 was shown to regulate Hedgehog signaling by deubiquitinating and stabilizing Smoothened, an effect enhanced by RPN13.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, genetic epistasis in Drosophila and mammalian cells\",\n      \"pmids\": [\"28992318\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"chain linkage on Smo not defined\", \"whether proteasome-associated or free UCH37 acts not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A series of disease-context studies established UCH37 as a recurrent NLRP3 deubiquitinase that stabilizes NLRP3 and promotes inflammasome activation across hepatocytes, mesenchymal stem cells, and vascular smooth muscle.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, siRNA/inhibitor, m6A regulation (RIP/luciferase) and in vivo models\",\n      \"pmids\": [\"34431717\", \"36778113\", \"37044315\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"direct interaction not uniformly demonstrated\", \"K63 vs stability mechanisms reported inconsistently across contexts\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Additional substrate links broadened UCH37's signaling reach, stabilizing PKC\\u03b1 with USP14 to drive NF-\\u03baB activation, stabilizing ELK3 in pancreatic cancer, ALK5 in chondrocytes, and ZRANB1 to modulate ferroptosis, while also influencing autophagic flux.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, knockdown/knockout, CHX-chase, autophagy flux and xenograft/in vivo models\",\n      \"pmids\": [\"40804247\", \"36328194\", \"37406898\", \"42037453\", \"39912491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"several rest on single-lab Co-IP without reciprocal validation\", \"direct vs proteasome-indirect mechanisms not separated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Genetic evidence established UCH37's essentiality in mammals, with knockout causing prenatal lethality and severe brain developmental defects.\",\n      \"evidence\": \"Conditional knockout mouse model with histological analysis\",\n      \"pmids\": [\"21048919\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"molecular pathway underlying the brain phenotype not identified\", \"which UCH37 substrates drive lethality unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How UCH37's many cytoplasmic/nuclear signaling substrates relate to its proteasome- and INO80-bound pools, and which engagements are direct catalytic versus scaffolding or proteasome-indirect, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"substrate-targeting rules for free vs complex-bound UCH37 undefined\", \"chain linkages cleaved on many substrates not directly determined\", \"no unifying model connecting developmental essentiality to specific substrate pathways\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 12, 18, 23]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 7, 13]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [4, 20, 29, 31]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [8, 13, 14]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 12, 13]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 20, 26]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [25, 29, 30]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [32]}\n    ],\n    \"complexes\": [\"26S proteasome (19S/PA700 regulatory particle)\", \"hINO80 chromatin-remodeling complex\"],\n    \"partners\": [\"ADRM1\", \"RPN2\", \"NFRKB\", \"Smad7\", \"Axin1\", \"ZRANB1\", \"NLRP3\", \"USP14\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}